Home » Topics » Regulatory » EMA

EMA
RSS

EMA committee gives positive opinion for Pfizer's Xeljanz

Jan. 30, 2017

EMA's CHMP supports approval of Revlimid for post-ASCT maintenance therapy in MM

Jan. 30, 2017

EMA grants accelerated assessment to glecaprevir/pibrentasvir MAA

Jan. 25, 2017

European orphan drug designation for Therabron's CG-367 for bronchiolitis obliterans syndrome

Jan. 24, 2017

Gilead Sciences' MAA for sofosbuvir/velpatasvir/voxilaprevir validated by EMA

Jan. 23, 2017

EMA awards orphan designation to Abeona Therapeutics' ABO-101

Jan. 20, 2017

FDA, EMA accept Boehringer Ingelheim's BI-695501 for review

Jan. 19, 2017

EMA accepts for review MAA for KRN-23 in X-linked hypophosphatemia

Jan. 5, 2017

Abeona Therapeutics' ABO-201 granted orphan drug designation in Europe

Jan. 4, 2017

FDA accepts betrixaban NDA for priority review, EMA validates MAA

Dec. 27, 2016

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...